Related Experiment Video
Updated: Aug 14, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Thrombosis and lung cancer]
1Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny, France. anne-marie.brechot@avc.ap-hop-paris.fr
Abstract:
Venous thromboembolism (TE) is a frequent occurrence in lung cancer patients and can be precipitated by venous stasis, the activation of clotting cascades by pro-coagulant tumour factors and by vascular injury due to chemotherapy and central venous catheters. Subcutaneous low molecular weight heparin (LMWH) has replaced intravenous unfractionated heparin in the treatment of acute TE. The use of long-term LMWH is recommended to prevent the recurrence of TE. Prophylactic treatment is indicated in patients undergoing surgery or hospitalised. Heparin appears to have distinct anti-neoplastic as well as anticoagulant effects, which benefit overall survival.
Related Concept Videos
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Other Pulmonary Disorders